Fisetin
CAS 528-48-3
Fisetin (CAS 528-48-3) is a Phase 2 pharmaceutical compound with 7 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 13727.14893939394 nM | 65 | - |
| - | GI50 | 18994.074237288132 nM | 59 | - |
| - | MIC | 31.975607719298242 ug.mL-1 | 57 | - |
| - | Potency | 17561.416949152543 nM | 38 | - |
| - | IC50 | 19.88125 ug.mL-1 | 16 | - |
| - | EC50 | 35213.333333333336 nM | 6 | - |
| - | Ki | 25925.6425 nM | 4 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Fisetin used for in pharmaceutical contexts?
Fisetin (CAS 528-48-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Fisetin?
No adverse-event association or SIDER side-effect rows are rendered for Fisetin in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Fisetin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for FISETIN with EU status "permitted".
What clinical phase is Fisetin in?
Fisetin is rendered with ChEMBL max phase 2.